Bectas Therapeutics is focused on developing monoclonal antibody therapies aimed at treating cancer, with a strong emphasis on precision medicine. The company is in the preclinical stage and is working on therapies that not only demonstrate best-in-class preclinical activity but also incorporate biomarkers to identify patients who are most likely to benefit from these treatments. Their approach combines advanced monoclonal antibodies that target secondary immune checkpoints, which play a crucial role in regulating myeloid-dependent suppression of the immune system. This strategy aims to enhance the immune response against tumors, thereby improving therapeutic outcomes across various cancer types.

The company’s mission is to harness the full potential of the immune system to deliver curative therapies for cancer patients. Bectas Therapeutics utilizes unique insights derived from human patient data to develop biomarkers that help in selecting the right patients for their therapies. This focus on understanding the dynamic responses of the immune system allows them to address the limitations of existing treatments, particularly for those patients who do not respond to current therapies. By combining innovative drug development with precision insights, Bectas Therapeutics aims to create first-in-class therapies that can significantly impact cancer treatment.

United States

Bectas Therapeutics is a preclinical-stage biotech company developing monoclonal antibody therapies for cancer accompanied by biomarkers to identify patients that will most benefit from each Bectas therapeutic antibody.

Our programs combine monoclonal antibodies that exhibit best-in-class pre-clinical activity with precision insights that enable first-in-class therapies to serve patients across multiple cancer indications

Bectas Therapeutics

Company Details